摘要
背景:研究表明,细胞因子参与炎症性疾病和血管疾病的发展。 目的:本研究探讨转化生长因子β(TGFβ)、白细胞介素6(IL6)、肿瘤坏死因子α(TNFα)和干扰素γ(IFNγ)随血栓闭塞性脉管炎(TAO)症状进展的变化。 方法:本研究纳入了 80 名 TAO 患者,他们从 2012 年到 2016 年从 Alavi 医院血管和血管内研究中心选出。然后将他们分为三组:轻度(迁移性血栓性静脉炎、冷敏感性或雷诺现象、和皮肤变色)、中度(慢性溃疡、跛行和夜间足部灼痛)和重度(休息时疼痛和自发性坏疽)症状。采用ELISA法测定血清TGFβ、IL6、TNFα、IFNγ水平并进行组间比较。 结果:前三个主要症状是脉搏障碍(n = 76, 95.00%)、怕冷(n = 61, 76.25%)和跛行(n = 59, 73.75%)。协方差分析 (ANCOVA) 的比较显示,随着症状的严重程度从中度到重度阶段的增加,TGFβ 和 IL6 均失调;然而,这种变化并不显着(p > 0.05)。在多元逻辑回归模型中,与严重症状相比,存在中度症状时 TNFα 水平升高(p < 0.05)。 结论:可以得出结论,作为 T 辅助细胞的定义细胞因子产生谱的一部分,TNFα 可以显着参与 TAO 从中度到重度阶段的进展。
关键词: 细胞因子、横断面研究、体征和症状、血栓闭塞性脉管炎、ELISA、疾病。
Current Molecular Medicine
Title:Cytokine Analysis in Patients with Different Stages of Thromboangiitis Obliterans
Volume: 21 Issue: 9
关键词: 细胞因子、横断面研究、体征和症状、血栓闭塞性脉管炎、ELISA、疾病。
摘要:
Background: Studies suggest that cytokines are involved in the development of both inflammatory disorders and vascular diseases.
Objective: The changes in transforming growth factor β (TGFβ), interleukin 6 (IL6), tumor necrosis factor α (TNFα), and interferon γ (IFNγ) with the progression of the thromboangiitis obliterans (TAO) symptoms were investigated in this research.
Methods: This study included 80 patients with TAO, who were selected from the Vascular and Endovascular Research Center in Alavi Hospital, from the year 2012 to 2016. They were then categorized into three groups: Mild (migratory thrombophlebitis, cold sensitivity or Raynaud's phenomenon, and skin discoloration), moderate (chronic ulcers, claudication, and burning pain of the feet at night), and severe (pain at rest and spontaneous gangrene) symptoms. The serum levels of TGFβ, IL6, TNFα, and IFNγwere determined by the ELISA method and compared among the groups.
Results: The first three predominant symptoms were pulse disorder (n = 76, 95.00%), cold intolerance (n = 61, 76.25%), and claudication (n = 59, 73.75%). A comparison of the analysis of covariance (ANCOVA) revealed that both TGFβ and IL6 were dysregulated as the severity of the symptoms increased from the moderate to the severe stages; however, such changes were not significant (p > 0.05). In the multiple logistic regression model, increased TNFα levels were seen in the presence of moderate symptoms as compared to the severe ones (p < 0.05).
Conclusion: It could be concluded that TNFα, as part of the defining cytokineproduction profile of T helper cells, can be significantly involved in the progression of TAO from the moderate to the severe stages.
Export Options
About this article
Cite this article as:
Cytokine Analysis in Patients with Different Stages of Thromboangiitis Obliterans, Current Molecular Medicine 2021; 21 (9) . https://dx.doi.org/10.2174/1566524020666201120112828
DOI https://dx.doi.org/10.2174/1566524020666201120112828 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Effects of Subhypothermia on Ca2+, Mg2+, Excitatory Amino Acids and Plasma Endothelin in Brain Tissues of Mice with Acute Cerebral Infarction
Vascular Disease Prevention (Discontinued) Nontuberculous Mycobacterium Infections in Rheumatoid Arthritis Patients: The Serodiagnosis of Pulmonary Disease due to Mycobacterium avium Complex with an Enzyme Immunoassay Kit Detecting Glycopeptidolipid Core Antigen (Capilia MAC Antibody ELISA)<sup>®</sup>)
Current Rheumatology Reviews Nanocarriers for Tracking and Treating Diseases
Current Medicinal Chemistry Drug-Induced Peripheral Neuropathy: Diagnosis and Management
Current Cancer Drug Targets Mitochondria in Cancer Stem Cells: A Target for Therapy
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Antioxidant Activity of Plant Phenols: Chemical Mechanisms and Biological Significance
Current Organic Chemistry Evidence for, and Importance of, cGMP-Independent Mechanisms with NO and NO Donors on Blood Vessels and Platelets
Current Vascular Pharmacology Inhibition of Angiogenesis by Non-Steroidal Anti-Inflammatory Drugs: From the Bench to the Bedside and Back
Current Drug Targets - Inflammation & Allergy Adverse Events of Proton Pump Inhibitors: Potential Mechanisms
Current Drug Metabolism Biomarkers of Chronic Kidney Disease - Mineral and Bone Disorder (CKD-MBD), A Review of Published Patents and Patent Applications
Recent Patents on Biomarkers PDE5 Inhibitor Treatment Options for Urologic and Non-Urologic Indications: 2012 Update
Current Pharmaceutical Design Inflammation in Fish As Seen from A Morphological Point of View with Special Reference to the Vascular Compartment
Current Pharmaceutical Design Microarray Profiling Analysis Uncovers Common Molecular Mechanisms of Rubella Virus, Human Cytomegalovirus, and Herpes Simplex Virus Type 2 Infections in ECV304 Cells
Current Molecular Medicine Vascular Endothelial Primary Cilia: Mechanosensation and Hypertension
Current Hypertension Reviews Hyper-Coagulable Profile with Elevated Pro-Thrombotic Biomarkers and Increased Cerebro- and Cardio-Vascular Disease Risk Exist Among Healthy Dyslipidemic Women
Current Neurovascular Research Immunossupressant and Organ Transplantation: Immunophilins Targeting Agent and Alternative Therapies
Current Medicinal Chemistry Medicinal Agents and Metabolic Syndrome
Current Medicinal Chemistry Targeting the Human Thioredoxin System by Diverse Strategies to Treat Cancer and Other Pathologies
Recent Patents on DNA & Gene Sequences Pharmacogenomics and Personalized Medicine for the Developing World - Too Soon or Just-in-Time? A Personal View from the World Health Organization
Current Pharmacogenomics and Personalized Medicine Cardioprotection by Targeting the Pool of Resident and Extracardiac Progenitors
Current Drug Targets